Genmab A/S ended 2018 with a cash balance of DKK 6.1 billion ($920 million), up by 13% from a year earlier as royalty revenue from its lead cancer product Darzalex (daratumumab), developed with Janssen Biotech Inc, continued to roll in. Darzalex is a monoclonal antibody that binds to the protein CD38 on multiple myeloma cells for the treatment of multiple myeloma. It is now approved for six indications in the US including, most recently, as a split dose regimen.
